Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “hold” rating reissued by equities research analysts at Needham & Company LLC in a research note issued on Wednesday.

The analysts wrote, “Intercept reported $40.9M in WW 3Q17 Ocaliva sales, with $4.1M attributed to one-time accounting adjustment. Excluding adjustment, WW and U.S. Ocaliva sales were $36.8M and $32.5M, respectively, both in-line with our and consensus $36M and $33M ests. Company has completed safety review w/ independent committee and discussions w/ FDA are underway. Changes to U.S. label are expected by early 1Q18. Safety concerns appear to have had modest impact on NRX since FDA letter and we have reduced our ests accordingly. Long-term sales in PBC may be negatively impacted by large number of competing programs in development. Maintain HOLD.””

A number of other research analysts also recently commented on the stock. Cowen and Company reaffirmed a “buy” rating and set a $112.00 price objective on shares of Intercept Pharmaceuticals in a research note on Wednesday. Cantor Fitzgerald raised shares of Intercept Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $69.00 price objective for the company in a research note on Wednesday. Laidlaw raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 price objective for the company in a research note on Wednesday. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, October 24th. Finally, Bank of America Corporation dropped their price objective on shares of Intercept Pharmaceuticals from $102.00 to $73.00 and set an “underperform” rating for the company in a research note on Friday, October 13th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $153.76.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, beating the Zacks’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 152.78%. The company had revenue of $41.33 million during the quarter, compared to the consensus estimate of $36.95 million. During the same quarter in the prior year, the company posted ($3.59) EPS. The company’s quarterly revenue was up 697.9% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: “Needham & Company LLC Reiterates Hold Rating for Intercept Pharmaceuticals, Inc. (ICPT)” was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/needham-company-llc-reiterates-hold-rating-for-intercept-pharmaceuticals-inc-icpt/1674470.html.

In other news, CMO David Shapiro sold 1,250 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $117.43, for a total transaction of $146,787.50. Following the completion of the transaction, the chief marketing officer now directly owns 45,812 shares in the company, valued at approximately $5,379,703.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Lisa Bright sold 253 shares of the stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of $111.31, for a total value of $28,161.43. Following the transaction, the insider now owns 23,324 shares of the company’s stock, valued at $2,596,194.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,069 shares of company stock valued at $325,974. Company insiders own 9.20% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. PNC Financial Services Group Inc. lifted its stake in Intercept Pharmaceuticals by 0.7% during the first quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock worth $229,000 after purchasing an additional 14 shares during the last quarter. Public Employees Retirement Association of Colorado lifted its stake in Intercept Pharmaceuticals by 1.1% during the second quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 43 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in Intercept Pharmaceuticals by 1.8% during the second quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock worth $416,000 after purchasing an additional 62 shares during the last quarter. WFG Advisors LP lifted its stake in Intercept Pharmaceuticals by 16.4% during the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 125 shares during the last quarter. Finally, Oppenheimer & Co. Inc. lifted its stake in Intercept Pharmaceuticals by 9.0% during the first quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 178 shares during the last quarter. Hedge funds and other institutional investors own 82.81% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.